Clinical trial NCT04807816: Targeting ATR in Soft-tissue Sarcomas
Official title: Targeting ATR in Soft-tissue Sarcomas: a Randomized Phase II Study. TARSARC Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Leiomyosarcoma, Adult
Keywords: ATR inhibition
soft-tissue sarcoma
advanced/metastatic
Lead sponsor: Institut Bergonié
Sponsor class: OTHER
Collaborators: name: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
First posted: 2021-03-19
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.
Primary purpose: TREATMENT

Brief summary: Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine

Detailed description: This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.

Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed leiomyosarcomas.
2. Metastatic or unresectable locally advanced disease,
3. Documented progression according to RECIST v1.1 confirmed by central review,
4. Age ≥ 18 years,
5. ECOG ≤ 1,
6. Life expectancy \> 3 months,
7. No more than 3 previous line of systemic therapy for advanced disease,
8. Patients must have advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgement,
9. Patients must have measurable disease defined as per RECIST v1.1
10. Patient must comply with the collection of tumor biopsies, and tumors must be accessible for biopsy,
11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy,
12. Adequate hematological, renal, metabolic and hepatic function
13. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization.
14. Both women of childbearing potential and men must agree to use a highly effective method of contraception 28 days before start of first dose of study drug
15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
16. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment
17. Voluntarily signed and dated written informed consent prior to any study specific procedure,
18. Patients with a social security in compliance with the French law.

Exclusion Criteria:

1. Previous treatment with Gemcitabine, or berzosertib or other ATR inhibitor,
2. Evidence of progressive or symptomatic central nervous system or leptomeningeal metastases,
3. Women who are pregnant or breast feeding,
4. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
5. Previous enrolment in the present study,
6. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
7. Known hypersensitivity to any involved study drug or any of its formulation components,
8. Has known active hepatitis B or hepatitis C,
9. Has a known history of Human Immunodeficiency Virus or known acquired immunodeficiency syndrome
10. Any of the following cardiac or cardiovascular criteria :

    * Congestive heart failure ≥ New York Heart Association (NHYA) class 1,
    * Unstable angina , new-onset angina
    * Myocardial infarction less than 6 months before start of study drug
    * Uncontrolled cardiac arrhythmias,
11. Participants with Li Fraumeni syndrome and/or ataxia telangiectasia,
12. Active autoimmune disease:

    * Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible,
    * Patients requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at dose ≤ 10 mg or 10 mg equivalent prednisone day,
    * Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intra-ocular or inhalation) are acceptable.
13. Arterial or venous thrombotic or embolic events such as cerebrovascular accident , deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication,
14. Patients with oral anticoagulation based on Vitamine K antagonist,
15. Treatment by potent inhibitors or inducers of CYP3A4
16. Vaccination with yellow fever or by any other live attenuated vaccine in the last 30 days,
17. Individuals deprived of liberty or placed under legual guardianship.

Primary outcomes:
measure: Assessment of the antitumor activity of berzosertib combined with gemcitabine
timeFrame: 6 months
measure: Assessment of the antitumor activity of gemcitabine
timeFrame: 6 months
Secondary outcomes:
measure: 6-month objective response rate (ORR) for patients treated by berzosertib in association with gemcitabine
timeFrame: 6 months
measure: 6-month objective response rate (ORR) for patients treated by gemcitabine alone
timeFrame: 6 months
measure: Best overall response for patients treated by berzosertib in association with gemcitabine
timeFrame: throughout the treatment period, an expected average of 6 months
measure: Best overall response for patients treated by gemcitabine alone
timeFrame: throughout the treatment period, an expected average of 6 months
measure: 1-year progression-free survival for patients treated by berzosertib in association with gemcitabine
timeFrame: 1 year
measure: 1-year progression-free survival for patients treated by gemcitabine alone
timeFrame: 1 year
measure: 2-year progression-free survival for patients treated by berzosertib in association with gemcitabine
timeFrame: 2 years
measure: 2-year progression-free survival for patients treated by gemcitabine alone
timeFrame: 2 years
measure: 1-year overall survival for patients treated by berzosertib in association with gemcitabine
timeFrame: 1 year
measure: 1-year overall survival for patients treated by gemcitabine alone
timeFrame: 1 year
measure: 2-year overall survival for patients treated by berzosertib in association with gemcitabine
timeFrame: 2 years
measure: 2-year overall survival for patients treated by gemcitabine alone
timeFrame: 2 years
measure: 6-month objective response according to CHOI criteria, independently for each arm
timeFrame: 6 months
measure: Best overall response according to CHOI criteria, independently for each arm
timeFrame: throughout the treatment period, an expected average of 6 months
measure: Safety profile independently for each arm: Common Terminology Criteria for Adverse Event version 5
timeFrame: throughout the treatment period, an expected average of 6 months
measure: Tumor immune cells levels
timeFrame: before treatment onset and cycle 2 day 1 (each cycle is 21 days)
measure: Blood cytokines levels
timeFrame: baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)
measure: Blood lymphocytes levels
timeFrame: baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)
measure: Blood kynurenine levels
timeFrame: baseline, cycle 2 day 1, cycle 6 day 1 and progression (each cycle is 21 days)
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Institut Bergonié
city: Lyon
country: France
facility: Centre Leon Berard
city: Poitiers
country: France
facility: CHU Poitiers
city: Saint-Herblain
country: France
facility: Institut de Cancérologie de l'Ouest
city: Toulouse
country: France
facility: IUCT Oncopôle
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
References: